GRITSTONE BIO INC (GRTS) Stock Price, Quote, News and Overview
NASDAQ:GRTS - Nasdaq - US39868T1051 - Common Stock - Currency: USD
GRTS Quote, Performance and Key Statistics
0.0322
-0.01 (-31.78%)
The current stock price of GRTS is 0.0322 USD. In the past month the price decreased by -94.46%. In the past year, price decreased by -98.3%.
GRTS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.34 | 333.26B | ||
| AMGN | AMGEN INC | 13.02 | 145.32B | ||
| GILD | GILEAD SCIENCES INC | 12.54 | 120.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.37B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.23 | 58.53B | ||
| ARGX | ARGENX SE - ADR | 94.66 | 33.93B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.24B | ||
| ONC | BEIGENE LTD-ADR | 5.81 | 25.07B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.50B | ||
| NTRA | NATERA INC | N/A | 20.22B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.55B | ||
| BIIB | BIOGEN INC | 7.51 | 17.41B |
Related stock screener links
About GRTS
Company Profile
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 231 full-time employees. The company went IPO on 2018-09-28. The firm discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. The company has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The company has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
Company Info
GRITSTONE BIO INC
5959 Horton Street, Suite 300
Emeryville CALIFORNIA 94608 US
CEO: Andrew Allen
Employees: 231
Phone: 15108716100
GRITSTONE BIO INC / GRTS FAQ
What is the stock price of GRITSTONE BIO INC today?
The current stock price of GRTS is 0.0322 USD. The price decreased by -31.78% in the last trading session.
What is the ticker symbol for GRITSTONE BIO INC stock?
The exchange symbol of GRITSTONE BIO INC is GRTS and it is listed on the Nasdaq exchange.
On which exchange is GRTS stock listed?
GRTS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GRITSTONE BIO INC stock?
6 analysts have analysed GRTS and the average price target is 0.77 USD. This implies a price increase of 2275.78% is expected in the next year compared to the current price of 0.0322. Check the GRITSTONE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GRITSTONE BIO INC worth?
GRITSTONE BIO INC (GRTS) has a market capitalization of 3.80M USD. This makes GRTS a Nano Cap stock.
How many employees does GRITSTONE BIO INC have?
GRITSTONE BIO INC (GRTS) currently has 231 employees.
Is GRITSTONE BIO INC (GRTS) expected to grow?
The Revenue of GRITSTONE BIO INC (GRTS) is expected to decline by -74.34% in the next year. Check the estimates tab for more information on the GRTS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GRITSTONE BIO INC (GRTS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GRTS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GRTS, evaluating the profitability, health, valuation and growth aspects
- GRITSTONE BIO INC (GRTS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GRITSTONE BIO INC (GRTS) Sales and EPS estimates to see what analysts future expectations are.
- GRITSTONE BIO INC (GRTS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GRITSTONE BIO INC (GRTS) Insider and Institutional Ownership to learn about the owners and their transactions.
- GRITSTONE BIO INC (GRTS) Stock Chart to make your own analysis
- GRITSTONE BIO INC (GRTS) Latest news and press-releases to stay up to date.
Does GRITSTONE BIO INC (GRTS) stock pay dividends?
GRTS does not pay a dividend.
When does GRITSTONE BIO INC (GRTS) report earnings?
GRITSTONE BIO INC (GRTS) will report earnings on 2024-11-07, after the market close.
What is the Price/Earnings (PE) ratio of GRITSTONE BIO INC (GRTS)?
GRITSTONE BIO INC (GRTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.09).
GRTS Technical Analysis
GRTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRTS. GRTS has a bad profitability rating. Also its financial health evaluation is rather negative.
GRTS Financial Highlights
Over the last trailing twelve months GRTS reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS increased by 13.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.33% | ||
| ROE | -599.53% | ||
| Debt/Equity | 1.83 |
GRTS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to GRTS. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 19.29% and a revenue growth -74.34% for GRTS